AAC
Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowReprints and Permissions
Right arrow Copyright Information
Right arrow Books from ASM Press
Right arrow MicrobeWorld
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Walzer, P. D.
Right arrow Articles by Cushion, M. T.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Walzer, P. D.
Right arrow Articles by Cushion, M. T.

 Previous Article  |  Next Article 

Antimicrobial Agents and Chemotherapy, November 2001, p. 3234-3237, Vol. 45, No. 11
0066-4804/01/$04.00+0   DOI: 10.1128/AAC.45.11.3234-3237.2001
Copyright © 2001, American Society for Microbiology. All rights reserved.

In Vitro and In Vivo Effects of Quinupristin-Dalfopristin against Pneumocystis carinii

Peter D. Walzer,1,2,* Alan Ashbaugh,2 Margaret Collins,2 and Melanie T. Cushion1,2

Research Service, Veterans Affairs Medical Center, Cincinnati, Ohio 45220,1 and Division of Infectious Diseases, University of Cincinnati College of Medicine, Cincinnati, Ohio 452672

Received 9 February 2001/Returned for modification 21 July 2001/Accepted 10 August 2001

Quinupristin-dalfopristin (Q-D), which is active against bacteria and Toxoplasma gondii, was examined for its activity against Pneumocystis carinii. After 72 h of incubation with rat P. carinii in an ATP cytotoxicity assay, the 50% inhibitory concentration of Q-D was 10.6 µg/ml, a level that can be achieved in serum with high-dose administration. Q-D administered intraperitoneally at doses of 50 to 200 mg per kg of body weight per day in the treatment and 100 mg/kg/day three times per week in the prophylaxis of pneumocystosis in immunosuppressed mice reduced the organism burden up to 15- and 302-fold, respectively. We conclude that Q-D has activity against P. carinii in vitro and in vivo.

* Corresponding author. Mailing address: Research Service (151), VA Medical Center, 3200 Vine St., Cincinnati, OH 45220. Phone: (513) 475-6328. Fax: (513) 475-6415. E-mail: peter.walzer{at}med.va.gov

Antimicrobial Agents and Chemotherapy, November 2001, p. 3234-3237, Vol. 45, No. 11
0066-4804/01/$04.00+0   DOI: 10.1128/AAC.45.11.3234-3237.2001
Copyright © 2001, American Society for Microbiology. All rights reserved.


This article has been cited by other articles:



Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
Clin. Vaccine Immunol. Clin. Microbiol. Rev.
J. Clin. Microbiol. ALL ASM JOURNALS

Copyright © 2001 by the American Society for Microbiology. All rights reserved.